Export 2761 results:
Author Title [ Type(Asc)] Year
Journal Article
J. Kobashigawa, Miller, L., Russell, S., Ewald, G., Zucker, M., Goldberg, L., Eisen, H., Salm, K., Tolzman, D., Gao, J., Fitzsimmons, W., First, M., and Investigators, S., “Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report”, Am J Transplant, vol. 6, pp. 1377-1386, 2006.
J. A. Kobashigawa, Miller, L. W., Russell, S. D., Ewald, G. A., Zucker, M. J., Goldberg, L. R., Eisen, H. J., Salm, K., Tolzman, D., Gao, J., Fitzsimmons, W., and First, R., “Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.”, Am J Transplant, vol. 6, no. 6, pp. 1377-86, 2006.
A. M. Neu, Ho, P. L., Furth, S. L., Fine, R. N., and Fivush, B. A., “Tacrolimus vs. Cyclosporine as primary immunosuppression in pediatric renal transplant patients: a North American Pediatric Renal Cooperative Study (NAPRTCS) Report”, 2001.
A. M. Neu, Ho, M., Furth, S. L., Fine, R. N., and Fivush, B. A., “Tacrolimus vs. Cyclosporine as Primary Immunosuppression in Pediatric Renal Transplant Patients: a naprtcs study”, 2002.
A. M. Neu, Ho, P. L., Fine, R. N., Furth, S. L., and Fivush, B. A., “Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study”, Pediatric Transplantation, vol. 7, pp. 217-222, 2003.
A. M. Neu, Ho, P. L. Martin, Fine, R. N., Furth, S. L., and Fivush, B. A., “Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.”, Pediatr Transplant, vol. 7, no. 3, pp. 217-22, 2003.
G. W. Burke, Kaufman, D. B., Bruce, D. S., Sutherland, D., Johnson, C. P., Gaber, A. O., Merion, R. M., Schweitzer, E., Marsh, C. L., Gruber, S. A., Alfrey, E., Leone, J. P., Conception, W., Stegall, M. D., Gores, P. S., Danovitch, G., Nunnally, P. J., Henning, A. K., and Fitzsimmons, W. E., “Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) +/- antibody induction in simultaneous pancreas kidney (SPK) transplantation: one year results”, 2001.
M. Lebwohl, Freeman, A. Krupnick, M Chapman, S., Feldman, S. R., Hartle, J. E., and Henning, A., “Tacrolimus ointment is effective for facial and intertriginous psoriasis.”, J Am Acad Dermatol, vol. 51, no. 5, pp. 723-30, 2004.
M. Lebwohl, Freeman, A. K., Chapman, M. S., ,, J Hartle, M. P. H., Henning, A. K., and Group, T. Ointment S., “Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis”, Journal of the American Academy of Dermatology, vol. 51, pp. 723-30, 2004.
A. Krupnick Freeman, Linowski, G. J., Brady, C., Lind, L., VanVeldhuisen, P., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.”, J Am Acad Dermatol, vol. 48, no. 4, pp. 564-8, 2003.
A. K. Freeman, Linowski, G. C., Brady, C., Lind, L., Van Veldhuisen, P., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas”, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
A. Krupnick, Serle, J., Van Veldhuisen, P., Lind, L., Clarke, J., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of eyelid dermatitis”, Cutis, vol. 73, pp. 267-71, 2004.
S. M. Bartosh and Stablein, D. M., “Tacrolimus as primary immunosuppression for children receiving non-primary renal transplants: A report of the North American Pediatric Cooperative Study (NAPRTCS)”, 2000.
I. Tellez, Sabbaj, S., Peng, X., Mulligan, M. J., and AVEG], theN. I. H. A. I. D. S. V., “T cell and antibody responses in HIV-1 seronegative volunteers immunized with recombinant canarypox and gp120 prime-boost vaccines”, 1999.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
M. Hudak, Chartrand, S., and Registry, S. Outcomes, “Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection - Patient Dempgraphics and Preliminary Results from 2000-2001 Synagis® Outcomes Registry”, J Perinatology, vol. 21, pp. 500-501, 2001.
I. Hand, Boron, M., and Van Veldhuisen, P., “Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry”, 2001.
M. Eydelman, Hilmantel, G., Tarver, M. E., Hofmeister, E. M., May, J., Hammel, K., Hays, R. D., and Ferris, F., “Symptoms and Satisfaction of Patients in the Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL) Studies.”, JAMA Ophthalmol, vol. 135, no. 1, pp. 13-22, 2017.
A. Girach, Aiello, L., Milton, R., Davis, M., Danis, R., Zhi, X., Sheetz, M., Vignati, L., and Group, P. K. C. - D. R. S. 2Study, “Sustained Moderate Visual Loss as a Predictive End Point for Visual Loss in Non-Proliferative Diabetic Retinopathy”, Eye (Lond), vol. 23, pp. 209-214, 2009.
A. Girach, Aiello, L. P., Milton, R. C., Davis, M. D., Danis, R. P., Zhi, X., Sheetz, M. J., and Vignati, L., “Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.”, Eye (Lond), vol. 23, no. 1, pp. 209-14, 2009.
M. E. Roland, Barin, B., Huprikar, S., Murphy, B., Hanto, D. W., Blumberg, E., Olthoff, K., Simon, D., Hardy, W. D., Beatty, G., and Stock, P. G., “Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls.”, AIDS, vol. 30, no. 3, pp. 435-44, 2016.
D. M. Stablein, Carter, W. H., and Wampler, G. L., “Survival analysis of drug combinations using a hazards model with time-dependent covariates.”, Biometrics, vol. 36, no. 3, pp. 537-46, 1980.
H. O. Douglass, Moertel, C. G., Mayer, R. J., Thomas, P. R., Lindblad, A. S., Mittleman, A., Stablein, D. M., and Bruckner, H. W., “Survival after postoperative combination treatment of rectal cancer.”, N Engl J Med, vol. 315, no. 20, pp. 1294-5, 1986.
A. S. Lindblad, Nolph, K. D., Novak, J. W., and Friedman, E. A., “A survey of the NIH CAPD Registry population with end-stage renal disease attributed to diabetic nephropathy.”, J Diabet Complications, vol. 2, no. 4, pp. 227-32, 1988.
M. G. Greiner, Shulman, M., Opara, O., Potter, K., Voronca, D. C., Tafessu, H. M., Hefner, K., Hamilton, A., Scheele, C., Ho, R., Dresser, L., Jelstrom, E., Fishman, M., Ghitza, U. E., Rotrosen, J., Nunes, E. V., and Bisaga, A., “Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study”, Contemp Clin Trials, vol. 128, p. 107148, 2023.